



12 November 2024

Sydney, Australia

## Nyrada Annual General Meeting Results

**Nyrada Inc (ASX:NYR)**, a drug discovery and development company focused on innovative Transient Receptor Potential Canonical (TRPC) ion channel blockers announces that at today's Annual General Meeting CDI Holders / Shareholders of the Company by way of poll:

1. passed Resolutions 1 to 7 (inclusive); and
2. did not pass Resolutions 8 to 11 (inclusive).

The results are set out in the attached document, in accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act.

-ENDS-

### About Nyrada Inc.

Nyrada Inc. is a biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, NYR-BI03, has shown efficacy in both neuroprotection and cardioprotection, positioning it for a first-in-human Phase I clinical trial. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, USA, with limited liability for its stockholders.

[www.nyrada.com](http://www.nyrada.com)

*Authorised by John Moore, Non-Executive Chair, on behalf of the Board.*

### Investors:

Dimitri Burshtein  
T: 02 9498 3390  
E: [info@nyrada.com](mailto:info@nyrada.com)

### Company Secretary:

David Franks  
T: 02 8072 1400  
E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

### Media Enquiries:

Catherine Strong  
Sodali & Co  
T: 0406 759 268  
E: [catherine.strong@sodali.com](mailto:catherine.strong@sodali.com)



### Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.

# Disclosure of Proxy Votes

Nyrada Inc

Annual General Meeting

Tuesday, 12 November 2024



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Re-election of Mr. John Moore as Director	P	36,355,606	36,248,563 99.71%	0 0.00%	33,419,911	107,043 0.29%	36,555,606 100.00%	0 0.00%	33,419,911	Carried
2 Re-election of Mr. Christopher Cox as Director	P	36,355,606	36,248,563 99.71%	0 0.00%	33,419,911	107,043 0.29%	36,555,606 100.00%	0 0.00%	33,419,911	Carried
3 Re-election of Dr. Ian Dixon as Director	P	36,255,606	36,107,650 99.59%	0 0.00%	33,519,911	147,956 0.41%	36,455,606 100.00%	0 0.00%	33,519,911	Carried
4 Re-election of Mr. Marcus Frampton as Director	P	35,237,198	35,130,155 99.70%	0 0.00%	34,538,319	107,043 0.30%	35,437,198 100.00%	0 0.00%	34,538,319	Carried
5 Re-election of Dr. Rüdiger Weseloh as Director	P	35,982,940	35,875,897 99.70%	0 0.00%	33,792,577	107,043 0.30%	36,182,940 100.00%	0 0.00%	33,792,577	Carried
6 Re-election of Dr. Gisela Mautner as Director	P	34,349,606	34,242,563 99.69%	0 0.00%	35,425,911	107,043 0.31%	34,549,606 100.00%	0 0.00%	35,425,911	Carried
7 ASX Listing Rule 7.1A Approval of Future Issue of Securities	P	69,712,184	69,408,572 99.56%	191,569 0.27%	63,333	112,043 0.16%	69,520,615 99.73%	191,569 0.27%	263,333	Carried
8 Approval of Issue of Incentive Securities to Mr. John Moore, Director of the Company	P	54,868,655	20,808,817 37.92%	33,952,795 61.88%	10,424,032	107,043 0.20%	20,915,860 38.12%	33,952,795 61.88%	10,624,032	Not Carried



Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
9 Approval of Issue of Incentive Securities to Mr. Christopher Cox, Director of the Company	P	54,868,655	20,808,817 37.92%	33,952,795 61.88%	10,424,032	107,043 0.20%	20,915,860 38.12%	33,952,795 61.88%	10,624,032	Not Carried
10 Approval of Issue of Incentive Securities to Mr. Marcus Frampton, Director of the Company	P	54,868,655	20,808,817 37.92%	33,952,795 61.88%	11,542,440	107,043 0.20%	20,915,860 38.12%	33,952,795 61.88%	11,742,440	Not Carried
11 Approval of Issue of Incentive Securities to Dr. Rüdiger Weseloh, Director of the Company	P	54,868,655	20,808,817 37.92%	33,952,795 61.88%	10,790,698	107,043 0.20%	20,915,860 38.12%	33,952,795 61.88%	10,990,698	Not Carried



personal use